These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24969128)

  • 1. Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain.
    Gulyás B; Sovago J; Gomez-Mancilla B; Jia Z; Szigeti C; Gulya K; Schumacher M; Maguire RP; Gasparini F; Halldin C
    Brain Struct Funct; 2015 Sep; 220(5):3043-51. PubMed ID: 24969128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal Characterization of mGluR5 Using
    Bertoglio D; Kosten L; Verhaeghe J; Thomae D; Wyffels L; Stroobants S; Wityak J; Dominguez C; Mrzljak L; Staelens S
    J Nucl Med; 2018 Nov; 59(11):1722-1727. PubMed ID: 29794227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL; Waldvogel HJ; Glass M; Faull RL
    J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
    Marshall PE; Landis DM; Zalneraitis EL
    Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum.
    Ferrante RJ; Kowall NW; Richardson EP; Bird ED; Martin JB
    Neurosci Lett; 1986 Nov; 71(3):283-8. PubMed ID: 2432445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylcysteine- and MK-801-induced changes in glutamate levels do not affect in vivo binding of metabotropic glutamate 5 receptor radioligand 11C-ABP688 in rat brain.
    Wyckhuys T; Verhaeghe J; Wyffels L; Langlois X; Schmidt M; Stroobants S; Staelens S
    J Nucl Med; 2013 Nov; 54(11):1954-61. PubMed ID: 24050937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping.
    Weeks RA; Cunningham VJ; Piccini P; Waters S; Harding AE; Brooks DJ
    J Cereb Blood Flow Metab; 1997 Sep; 17(9):943-9. PubMed ID: 9307607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington's disease.
    Ribeiro FM; Hamilton A; Doria JG; Guimaraes IM; Cregan SP; Ferguson SS
    Expert Opin Ther Targets; 2014 Nov; 18(11):1293-304. PubMed ID: 25118797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
    Ouattara B; Gasparini F; Morissette M; Grégoire L; Samadi P; Gomez-Mancilla B; Di Paolo T
    J Neurochem; 2010 May; 113(3):715-24. PubMed ID: 20132464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET.
    DuBois JM; Rousset OG; Rowley J; Porras-Betancourt M; Reader AJ; Labbe A; Massarweh G; Soucy JP; Rosa-Neto P; Kobayashi E
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):152-162. PubMed ID: 26290423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans.
    Hulka LM; Treyer V; Scheidegger M; Preller KH; Vonmoos M; Baumgartner MR; Johayem A; Ametamey SM; Buck A; Seifritz E; Quednow BB
    Mol Psychiatry; 2014 May; 19(5):625-32. PubMed ID: 23628984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.
    Leuzy A; Zimmer ER; Dubois J; Pruessner J; Cooperman C; Soucy JP; Kostikov A; Schirmaccher E; Désautels R; Gauthier S; Rosa-Neto P
    Brain Struct Funct; 2016 Apr; 221(3):1387-402. PubMed ID: 25596865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688.
    Ametamey SM; Treyer V; Streffer J; Wyss MT; Schmidt M; Blagoev M; Hintermann S; Auberson Y; Gasparini F; Fischer UC; Buck A
    J Nucl Med; 2007 Feb; 48(2):247-52. PubMed ID: 17268022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis.
    Sapp E; Ge P; Aizawa H; Bird E; Penney J; Young AB; Vonsattel JP; DiFiglia M
    Neuroscience; 1995 Jan; 64(2):397-404. PubMed ID: 7535402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated brain iron is independent from atrophy in Huntington's Disease.
    Dumas EM; Versluis MJ; van den Bogaard SJ; van Osch MJ; Hart EP; van Roon-Mom WM; van Buchem MA; Webb AG; van der Grond J; Roos RA;
    Neuroimage; 2012 Jul; 61(3):558-64. PubMed ID: 22480728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
    Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
    Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of Metabotropic Glutamate Receptor 5 Availability With Both [
    Glorie D; Verhaeghe J; Miranda A; De Lombaerde S; Stroobants S; Staelens S
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2022 Jun; 7(6):607-615. PubMed ID: 34856382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabotropic glutamate receptor 5 radioligand [
    Varnäs K; Juréus A; Finnema SJ; Johnström P; Raboisson P; Amini N; Takano A; Stepanov V; Halldin C; Farde L
    Neuropharmacology; 2018 Jun; 135():455-463. PubMed ID: 29608920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian variation of metabotropic glutamate receptor 5 availability in the rat brain.
    Elmenhorst D; Mertens K; Kroll T; Oskamp A; Ermert J; Elmenhorst EM; Wedekind F; Beer S; Coenen HH; Bauer A
    J Sleep Res; 2016 Dec; 25(6):754-761. PubMed ID: 27357735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease.
    Buck SH; Burks TF; Brown MR; Yamamura HI
    Brain Res; 1981 Mar; 209(2):464-9. PubMed ID: 6164436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.